恶性胆道梗阻金属支架置入后胆囊炎的危险因素与治疗策略:一项多中心回顾性研究
该多中心回顾性研究纳入1084例远端恶性胆道梗阻(DMBO)和353例肝门部恶性胆道梗阻(HMBO)患者,评估自膨式金属支架(SEMS)置入后胆囊炎的发生率、治疗及预测因素。DMBO和HMBO患者胆囊炎发生率分别为7.5%和5.9%。内镜治疗的复发率显著低于经皮治疗(P=.043),无复发生存期显著更长(P=.039)。EUS引导下胆囊引流(EUS-GBD)在技术成功率、操作时间和无复发生存期方面优于内镜下经乳头胆囊引流。肿瘤(P=.015)和支架(P=.037)阻塞胆囊管开口是DMBO患者胆囊炎的独立危险因素。
要点
- DMBO和HMBO患者SEMS置入后胆囊炎发生率相似,分别为7.5%和5.9%。
- 胆囊炎治疗中,内镜治疗的复发率显著低于经皮治疗(P=.043),无复发生存期显著更长(P=.039)。
- EUS-GBD在技术成功率、操作时间和无复发生存期方面优于内镜下经乳头胆囊引流。
核心结论
- DMBO和HMBO患者SEMS置入后胆囊炎发生率相似。
- EUS-GBD是MBO患者SEMS置入后胆囊炎的最佳治疗选择。
研究设计与样本
- 多中心回顾性研究,纳入2012年1月至2021年3月在12家机构接受SEMS置入的1084例DMBO患者和353例HMBO患者。
- 回顾性评估胆囊炎的发生率、治疗及预测因素。
主要发现
- DMBO患者胆囊炎发生率为7.5%,HMBO患者为5.9%。
- 胆囊炎治疗中,内镜治疗的复发率显著低于经皮治疗(P=.043),无复发生存期显著更长(P=.039)。
- EUS-GBD在技术成功率、操作时间和无复发生存期方面优于内镜下经乳头胆囊引流。
- DMBO患者中,肿瘤阻塞胆囊管开口(P=.015)和支架阻塞胆囊管开口(P=.037)是胆囊炎的独立危险因素。
- HMBO患者中,多次SEMS置入(OR=11,95%CI 0.68-190,P=.091)和胆囊结石(OR=2.3,95%CI 0.92-5.6,P=.075)与胆囊炎风险升高相关。
关键数值与推荐
- DMBO患者胆囊炎发生率7.5%,HMBO患者5.9%。
- 内镜治疗对比经皮治疗:复发率显著更低(P=.043),无复发生存期显著更长(P=.039)。
- EUS-GBD在技术成功率、操作时间和无复发生存期方面优于内镜下经乳头胆囊引流。
- DMBO中肿瘤阻塞胆囊管开口(P=.015)和支架阻塞胆囊管开口(P=.037)为独立危险因素。
- HMBO中多次SEMS置入OR=11(95%CI 0.68-190,P=.091),胆囊结石OR=2.3(95%CI 0.92-5.6,P=.075)。
临床怎么用
- 对于MBO患者SEMS置入后发生胆囊炎,EUS-GBD是最佳治疗选择。
- 内镜治疗在复发率和无复发生存期方面优于经皮治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Cholecystitis can occur after self-expandable metallic stent (SEMS) placement for malignant biliary obstruction (MBO), but the best treatment option for cholecystitis has not been determined. Here, we aimed to identify the risk factors of cholecystitis after SEMS placement and determine the best treatment option. METHODS: Incidence, treatments, and predictive factors of cholecystitis were retrospectively evaluated in 1084 patients with distal MBO (DMBO) and 353 patients with hilar MBO (HMBO) who underwent SEMS placement at 12 institutions from January 2012 to March 2021. RESULTS: Cholecystitis occurred in 7.5% of patients with DMBO and 5.9% of patients with HMBO. The recurrence rate was significantly lower (P = .043) and the recurrence-free period significantly longer (P = .039) in endoscopic procedures than in percutaneous procedures for cholecystitis treatment. EUS-guided gallbladder drainage (EUS-GBD) was better in terms of technical success, procedure time, and recurrence-free period than endoscopic transpapillary gallbladder drainage. Obstruction across the cystic duct orifice by tumor (P = .015) and by stent (P = .037) were independent risk factors for cholecystitis in DMBO. Cases with multiple SEMS placements (odds ratio [OR], 11; 95% confidence interval [CI], 0.68-190; P = .091) and with gallbladder stones (OR, 2.3; 95% CI ,0.92-5.6; P = .075) had a higher risk for cholecystitis in HMBO. CONCLUSIONS: The incidences of cholecystitis after SEMS placement for DMBO and HMBO were similar. EUS-GBD is the optimal treatment option for patients with cholecystitis after SEMS placement for MBO.
引用
- Matsumi A, Kato H, Ogawa T, et al. Risk factors and treatment strategies for cholecystitis after metallic stent placement for malignant biliary obstruction: a multicenter retrospective study. Gastrointest Endosc. 2024. PMID: 38490459. doi:10.1016/j.gie.2024.02.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。